Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

o4/o3/13	Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13		
Name o	of entity		
RCR To	mlinson Ltd		
ADM			
ABN	000.400		
81 008	898 486		
Part	he entity) give ASX the followin  1 - All issues  ust complete the relevant sections (attack	ch sheets if there is not enough space).	
1	*Class of *securities issued or to be issued	Performance Rights (unlisted)	
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	1,795,540 Performance Rights (Unlisted)	

Appendix 3B Page 1 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

- Principal terms of the 3 +securities (e.g. if options, exercise price and expiry date; if paid \*securities, the partly amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)
- (1) **588,240** Performance Rights issued to Managing Director and approved by shareholders on 25 October 2016; and
- (2) **1,207,300** Performance Rights issued to other group executives.

#### Performance Rights -Key Terms

Performance Rights are issued under the terms of the RCR Performance Incentive Plan approved by shareholders on 6 November 2015.

The proposed grant of Performance Rights will be subject to at least two (and potentially three) separate performance criteria measured over the three year performance period ending 30 June 2019:

- 50% of the Performance Rights will be subject to RCR achieving between 5% and 15% annual compound growth in Earnings Per Share ("EPS Hurdle"); and
- 50% of the Performance Rights will be subject to RCR's relative Total Shareholder Return ("TSR") performance, measured against a comparator group of peer companies ("TSR Hurdle").

The proposed terms for the grant of Performance Rights include an ability for the Board to introduce a third performance measure being an Economic Value Add ("EVA") measure. If the additional performance measure or similar value creation measure ("EVA Hurdle") is introduced then the Performance Rights will be split as follows, 50% to the EPS Hurdle, 25% to the TSR Hurdle and 25% to the EVA Hurdle.

To the extent that the performance criteria is not satisfied, the Performance Rights will lapse.

On exercise, each vested Performance Right carries a right to receive one fully paid ordinary share plus additional shares equal to the number calculated by dividing the value of the dividends that would have been earned by the prevailing end-of-day share price at the time that dividends are paid (rounded up to the nearest whole number).

No amount is payable upon the issue or exercise of Performance Rights.

Performance Rights that vest may be exercised (i.e. converted into ordinary shares) no later than 15 years after the grant date.

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

4 Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted \*securities?

If the additional \*securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

**Performance Rights** - Upon conversion of the Performance Rights into fully paid ordinary shares, the allotted and issued shares will rank equally in all respects with an existing class of quoted fully paid ordinary shares.

The Performance Rights do not have any voting rights or rights to receive dividends.

5 Issue price or consideration

The Performance Rights are issued as part of the Managing Director's and other executive's remuneration arrangements and accordingly are issued for no consideration.

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)

Grant of long-term incentives to the Managing Director and other executives.

6a Is the entity an \*eligible entity that has obtained security holder approval under rule 7.1A?

Not applicable

If Yes, complete sections 6b – 6h in relation to the \*securities the subject of this Appendix 3B, and comply with section 6i

6b The date the security holder resolution under rule 7.1A was passed

Not applicable

6c Number of \*securities issued without security holder approval under rule 7.1

Not applicable

6d Number of \*securities issued with security holder approval under rule 7.1A

Not applicable

04/03/2013 Appendix 3B Page 3

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Not applicable	
6f	Number of *securities issued under an exception in rule 7.2	Not applicable	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	Not applicable	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	Not applicable	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Not applicable	
-	<sup>+</sup> Issue dates	On or about 20 February 2	0017
7	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	On or about 20 rebrudly 2	.017.
		<b>_</b>	
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	Number 139,963,412	+Class Fully Paid Ordinary Shares
		·	

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Number and +class of all 9 +securities not quoted on ASX (including the +securities in section 2 if applicable)

Number	+Class	
50,000	Performance Rights	
	vesting, 28 Feb 2017 and 28 Feb 2018 (RCRAQ)	
	20 1 ED 2010 (NCNAQ)	
100,000	Performance Rights vesting	
·	1 Jul 2017 (RCRAQ)	
1,165,220	Performance Rights vesting	
	31 Aug 2017 (RCRAQ)	
200,000	Performance Rights vesting	
200,000	4 January 2018, 4 January	
	2019 and 4 January 2020,	
	but expiring 1 March 2031	
	(RCRAQ)	
2 170 200	Dorformanco Diahte vestina	
2,179,200	Performance Rights vesting 30 Aug 2018, but expiring	
	29 June 2031 and 14 July	
	2031 (RCRAQ)	
	•	
1,795,540	Performance Rights vesting	
	30 Aug 2019, but expiring	
	20 Feb 2032 (RCRAQ)	
Note that since the last Appendix 3B: Performance Rights (RCRAO) 790 250 have lanced and 1 164 275 have vested		

(RCRAQ) 790,250 have lapsed and 1,164,275 have vested.

Dividend policy (in the case of a 10 trust, distribution policy) on the increased capital (interests)

Performance Rights do not participate in dividends.

### Part 2 - Pro rata issue

11	Is security holder approval required?	Not applicable
12	Is the issue renounceable or non-renounceable?	Not applicable
13	Ratio in which the *securities will be offered	Not applicable
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	Not applicable
15	<sup>+</sup> Record date to determine entitlements	Not applicable
16	Will holdings on different registers (or subregisters) be aggregated for calculating	Not applicable

entitlements?

04/03/2013 Appendix 3B Page 5

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B New issue announcement

17	Policy for deciding entitlements in relation to fractions	Not applicable
18	Names of countries in which the entity has security holders who will not be sent new offer documents	Not applicable
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	Not applicable
20	Names of any underwriters	Not applicable
21	Amount of any underwriting fee or commission	Not applicable
22	Names of any brokers to the issue	Not applicable
23	Fee or commission payable to the broker to the issue	Not applicable
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	Not applicable
25	If the issue is contingent on security holders' approval, the date of the meeting	Not applicable
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	Not applicable
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	Not applicable
28	Date rights trading will begin (if applicable)	Not applicable
29	Date rights trading will end (if applicable)	Not applicable

See chapter 19 for defined terms.

Appendix 3B Page 6 04/03/2013

30		do security holders sell entitlements <i>in full</i> through ser?	Not applicable	
31			Not applicable	
32	How do security holders dispose of their entitlements (except by sale through a broker)?		Not applicable	
33	+Issue	date	Not applicable	
		uotation of securitie	<b>S</b> – <b>Not Applicable</b> oplying for quotation of securities	
34	Type (tick o	of <sup>+</sup> securities one)		
(a)		<sup>+</sup> Securities described in Part	1	
(b)		All other <sup>+</sup> securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities		
Entitie	es that	t have ticked box 34(a)		
	indicate	securities forming a new you are providing the informat		
35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders		
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories  1 - 1,000  1,001 - 5,000  5,001 - 100,000  100,001 - 100,000  100,001 and over			
37		A copy of any trust deed for	the additional *securities	

04/03/2013 Appendix 3B Page 7

<sup>+</sup> See chapter 19 for defined terms.

### Entities that have ticked box 34(b)

	• •		
38	Number of *securities for which *quotation is sought	Not applicable	
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought	Not applicable	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Not applicable	
	If the additional *securities do not rank equally, please state:  the date from which they do  the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  the extent to which they do not rank equally, other than in relation to the next dividend,		
	distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period	Not applicable	
	(if issued upon conversion of another *security, clearly identify that other *security)		
		N7 1	101
		Number	+Class
42	Number and *class of all *securities quoted on ASX ( <i>including</i> the *securities in clause 38)	Not applicable	

See chapter 19 for defined terms.

Appendix 3B Page 8 04/03/2013

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the †securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Darryl Edwards Company Secretary

Date: 25 January 2017

04/03/2013 Appendix 3B Page 9

<sup>+</sup> See chapter 19 for defined terms.